{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-023671","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2023-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.878713+00:00","generated_at":"2026-06-13T15:41:56.347149+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Foghorn Therapeutics reports Phase 1 data for FHD-286 in uveal melanoma, will not advance independently","bullets":["Phase 1 dose escalation study of FHD-286 in 73 metastatic uveal melanoma patients showed safety and tolerability; most common adverse events were dysgeusia, fatigue, AST increase.","One patient achieved durable partial response (>16 months on treatment), nine patients had stable disease, and tumor reductions were observed in eight patients.","Company will not advance FHD-286 in uveal melanoma; plans to initiate combination study with decitabine or cytarabine in relapsed/refractory AML in Q3 2023.","Preliminary immune modulation markers in tumor microenvironment support combination with checkpoint inhibitors; full results to be presented at future scientific meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-023671","json":"https://secwatch.observer/filing/0001628280-23-023671.json","markdown":"https://secwatch.observer/filing/0001628280-23-023671.md","text":"https://secwatch.observer/filing/0001628280-23-023671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023023671/0001628280-23-023671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023023671/fhtx-20230628.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:41:56.347149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}